1 SAE Centralized Report and Review Process April 2012.

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Adverse Events and Serious Adverse Events
Safety Reporting IN Clinical Trials
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
Chicken Soup for the Busy Coordinator Aug Scenario: Aim: Randomised, double-blind, phase III clinical trial to compare the safety and efficacy of.
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Capturing and Reporting Adverse Events in Clinical Research
John Naim, PhD Director Clinical Trials Research Unit
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.
Andrew Thornton Chairman, HREC Royal Adelaide Hospital Ethics Forum – June 2013.
New Adverse Event Reporting Policy Effective September 1, 2007.
Adverse Event Reporting.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
SAE Reporting Judy Breed, BA, RN June, 2011 CONFIDENTIAL.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
FDA Regulatory and Compliance Symposium
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
Medidata Rave Start-Up Information
Office of Human Research (OHR) Quality Improvement Program Patrick Herbison Heather Krupinski.
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
The Role and Responsibilities of the Clinical Research Coordinator

Responsibilities of Sponsor, Investigator and Monitor
Reportable Events Emory IRB 9/11/2014.
Safety Reporting Carrie Bayliss.
IRB reporting updates.
The Information Professional’s Role in Product Safety
Reportable Events & Other IRB Updates February 2017
Safety Reporting Nichol McBee, MPH, CCRP.
Adverse Event Reporting: Trials and Tribulations
Within Trial Decisions: Unblinding and Termination
Remote Monitoring of Adverse Events
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Remote Monitoring of Adverse Events
SERIOUS ADVERSE EVENTS REPORTING
Streamlining IRB Procedures for Expanded Access
Adverse Event Reporting _____________________________
Good clinical practice
Serious Adverse Event Reconciliation
Presentation transcript:

1 SAE Centralized Report and Review Process April 2012

2 AE/SAE Reporting and AdEERS Effective June 4, 2012 RTOG will be utilizing the centralized reporting pathway in AdEERS. This presentation will outline how centralized reporting for AE/SAE will be done –Your role in this process (site investigator and site research associate) –The role of RTOG (AE Coordinator) –Helpful information for reporting As stated in the accompanying memo impact on clinical sites will be minimal.

3 Points to remember about Ad EERS All SAEs are required to be reported regardless of grade, attribution or expectedness, unless specified in the Specific Protocol Exceptions to Expedited Reporting (SPEER). The AdEERS Report does not require or capture a determination of expectedness from the site investigator Section 7.0 of the protocol provides specific NCI required instructions regarding the reporting of SAEs for each study. There will also be a list of expected SAEs that do not require reporting.

4 Current AdEERS Reporting Pathway The participating site submits the report directly to the NCI and the FDA (as applicable). RTOG HQ, the Study Chair and the supporting pharmaceutical company are also copied automatically on the electronic AdEERS submission.

5 NEW Centralized Reporting Pathway (effective June 4 th, 2012) The participating site submits the report directly to the RTOG and RTOG submits to the FDA (as applicable). NCI the Study Chair and the supporting pharmaceutical company are also copied automatically on the electronic AdEERS submission by RTOG.

6 Site Investigator & Research Associate The role of the site RA (aka Reporter): –Report all SAEs via AdEERS –Notify RTOG of all unexpected and reasonably related Grade 4 and 5 SAE within 24 hours of becoming aware of the event –The associated complete report must be submitted within five calendar days –Report all other SAEs to RTOG within ten calendar days. The role of the site investigator: –Assists the RA/Reporter in providing a complete and accurate summary of the event –Provides sign off and retains responsibility for the completeness and accuracy of the report

7 AE/SAE Coordinator The role of the RTOG AE Coordinator: –To coordinate the timely review of submitted information, perform necessary edits for accuracy & clarity and submit reports of all UNEXPECTED and RELATED SAEs to the NCI, pharmaceutical sponsor and to the FDA as applicable and required by regulations. –Evaluates SAEs against the IB, the ICF, and the available literature in order to assess expectedness of the event. –Queries sites to resolve discrepancies. –Submits expedited reports to Health Canada as appropriate. –Tracks serious adverse event reports

8 Centralized reporting changes summarized In order to meet regulatory reporting deadlines, a collaborative effort between the RTOG AE Coordinator and the clinical site investigator and reporter is paramount. The site reporter and investigator will need to promptly address queries to ensure the accuracy of the AdEERS report. For unexpected and reasonably related SAE, a collaboration between the AE Coordinator, the clinical site and the Study Chair is essential to evaluate events appropriate for FDA reporting.

9 The Essentials of a Good SAE Report Structured in a coherent chronological format Avoid subjective language and use concrete values to describe an event. Clearly indicate whether the event is unexpected and related. –Most SAEs do not uniquely contribute to the safety profile of the drug, the FDA wants to review only unexpected and related SAEs. –Does this individual case change the safety profile of the drug? –Does this event warrant changes to the study protocol and/or to the informed consent form?

10 How to evaluate expectedness and relatedness Is there a temporal relationship between both onset and abatement of symptoms and drug start and stop dates respectively? Is the event documented in the Investigator Brochure? Is this event of a severity greater than expected according to the IB and/or protocol? Did this event occur with the first dose and at a severe grade? Can the contribution of the study drug to the SAE be unequivocally ruled out?

11 It’s a Team Effort Only a concerted team effort will allow for the timely submission of the necessary information to ensure patient safety Please remain especially vigilant for correspondence from the AE Coordinator related to all unexpected, related SAE Reports you have submitted The Timeline clock –Begins with the initial submission to RTOG –Fatal/Life threatening SAEs require submission to outside regulatory authorities in 5 calendar days –All other SAEs require submission to outside regulatory authorities in 10 calendar days

12 AE/SAE Coordinator Sara McCartney Please feel free to contact Sara directly with any questions.